[Syllabus]: MRI Case Conference

Steven Poplack, MD, FACR, FSBI

Steven Poplack, MD, FACR, FSBI(bio)

  • Professor of Radiology
  • Department of Radiology, Stanford University School of Medicine

Introduction

This case-based syllabus synthesizes practical principles for interpreting and managing findings on breast MRI. Through a spectrum of examples—ranging from tiny foci to extensive non-mass enhancement (NME), preoperative evaluation, neoadjuvant response, technical quality pitfalls, and extramammary findings—it emphasizes BI-RADS-consistent decision-making, multidisciplinary coordination, and the indispensable role of mammographic correlation. The course also highlights recurrence of specific pathologies (e.g., clustered ring NME and DCIS; apocrine metaplasia on MR biopsy), the impact of background parenchymal enhancement (BPE) on risk, and how to avoid common interpretive and management errors.

Risk Assessment and Screening Indications

MRI screening was illustrated in women labeled “high-risk,” including those reported with GAIL model estimates. GAIL is not the preferred model for MRI eligibility, yet it is frequently used clinically due to accessibility.

Key Points

  • The GAIL model is commonly used but is suboptimal for determining MRI eligibility; consider risk models that incorporate family history/genetics (e.g., Tyrer–Cuzick).
  • Document the risk model used and its limitations when MRI screening decisions are made.
  • MRI screening protocols should be contextualized by genetics (e.g., BRCA1/2), prior chest radiation, and clinical risk beyond GAIL scores.

Interpreting and Managing MRI Foci

Foci are “dots of enhancement too small to characterize,” distinct from background parenchymal enhancement (BPE). Interpretation relies on T2 signal, delayed kinetics, and change from priors, not strict size cutoffs.

Key Points

  • BI-RADS definition: If margins/shape/internal features can be characterized, it is not a focus.
  • Benign/probably benign features: T2 hyperintensity (light-bulb bright, like lymph nodes), persistent kinetics, stability.
  • Suspicious features: T2 hypointensity, washout kinetics, interval change; new T2-hypointense foci carry higher cancer risk.
  • Evidence: Meyers et al. (AJR 2020)—BI-RADS 3 foci <2% malignancy; BI-RADS 4 foci ~18% (4B range); larger size and washout favored BI-RADS 4 categorization.
  • Practical algorithm (ECOG-ACRIN 1141, abbreviated MRI): T2 hyperintense → benign; if not T2 hyperintense and rim enhancement → biopsy; if no rim → 6-month follow-up; confirm T1 hyperintensity as benign when applicable.

Non-Mass Enhancement (NME): Descriptors, Etiologies, and Management

NME requires precise description by distribution and internal enhancement pattern. Linear/segmental patterns often reflect ductal/pathologic processes.

Key Points

  • Distribution: focal, linear, segmental, regional, multiple regions. Segmental and linear patterns are higher-risk (ductal).
  • Internal enhancement: clustered ring (most specific), clumped/heterogeneous (more sensitive), homogeneous (least predictive).
  • Etiologic associations: Clumped linear or segmental NME—commonly DCIS; washout kinetics suggest invasive carcinoma or high-grade DCIS.
  • Management: Avoid BI-RADS 3 for linear/segmental NME; correlate with mammography to identify calcifications enabling easier (stereo/tomo) biopsy.

Clustered Ring NME and DCIS Correlation

Clustered ring is a classic internal enhancement pattern with high PPV for DCIS.

Key Points

  • Imaging appearance: “Cobblestone” or tiny ring-like enhancement.
  • Correlates with mammographic segmental calcifications (often pleomorphic/round).
  • Original description: Tozaki et al., AJR 2006; retained as an NME descriptor in BI-RADS 5th ed.
  • Expect DCIS extent to exceed invasive size; plan biopsy strategy and surgery accordingly.

Mammographic Correlation in MRI Interpretation and Biopsy Planning

Systematic mammographic correlation is essential to avoid overcalling MRI and to guide biopsy by the simplest modality.

Key Points

  • Review current or recent (≤12 months) mammography before final MRI assessment in mammography-age patients.
  • Use mammography to confirm suspicious MRI findings and to select biopsy guidance (stereotactic/tomosynthesis vs MRI-guided).
  • Consider scheduling strategies: Same-day vs staggered (alternating mammogram and MRI every 6 months); staggered may reduce interval cancers and anxiety in practice.

Assessing Response to Neoadjuvant Systemic Therapy

MRI is the modality of choice for monitoring neoadjuvant therapy (NAT).

Key Points

  • Always obtain a pre-NAT baseline MRI for comparison (ACR Appropriateness Criteria).
  • RECIST 1.1 approach: Complete response—disappearance; partial response—>30% decrease in longest diameter; progression—>20% increase.
  • Expected kinetic evolution: Downgrading from washout to plateau/persistent; reduced early enhancement intensity.
  • Track both size and kinetic profile changes to inform surgical planning.

Characterizing Benign-Oval Masses and Fibroadenomas on MRI

Oval, circumscribed, T2-hyperintense masses with persistent kinetics commonly represent fibroadenomas; multiplicity favors benignity.

Key Points

  • Internal enhancement: Dark internal septations support fibroadenoma; heterogeneous enhancement can blur distinction.
  • Multiplicity rule: Multiple similar masses may be considered characteristically benign; single masses often managed as probably benign with targeted ultrasound confirmation.
  • Second-look ultrasound supports benign characterization and determines follow-up modality.

Preoperative MRI: Additional Lesions, BI-RADS Strategy, and Multidisciplinary Workflow

Preoperative MRI frequently detects additional lesions; management must balance accuracy with procedural efficiency.

Key Points

  • Do not assign BI-RADS 3 in the preoperative ipsilateral breast; avoid 6-month follow-up in this setting.
  • Use a “forced” final BI-RADS (avoid 0) after completing appropriate correlation/targeted imaging to prevent stalled workflows.
  • Biopsy all additional lesions that may change management; coordinate with the surgeon to define how many/which lesions are needed to shift from BCT to mastectomy.
  • Exceptions (practice-based, limited evidence): Very close satellites in large breasts may be excised without biopsy; extremely suspicious correlates (4C–5) likely require excision regardless of biopsy.
  • Spatial planning: AP separation is overestimated on prone MRI; right-left and superior-inferior distances are more translatable to supine operative positioning.
  • Literature context: COMICE (early negative results due to limited biopsy of MRI-detected lesions); newer studies suggest MRI reduces reoperation when surgeon and workflow variables are controlled (e.g., Sung). Patients most likely to benefit: ILC, HER2+, TNBC, dense breasts, young age, node-positive, or mammo–US discordance/tip-of-the-iceberg scenarios (Monticciolo, Academic Radiology 2017).

Technical Adequacy and Quality Control in Breast MRI

Technical pitfalls can render MRI non-diagnostic; inadequate contrast enhancement may obscure cancers.

Key Points

  • Check positioning, homogeneous fat suppression, motion, and adequate parenchymal enhancement on early post-contrast.
  • A noisy MIP with poor depiction of breast vasculature suggests suboptimal enhancement; consider repeat exam.
  • Communicate with technologists regarding contrast delivery, timing, and injection issues; document repeat-imaging rationale.
  • Assign BI-RADS 0 when technical inadequacy precludes interpretation; repeat promptly.

Recognizing and Managing Extramammary Findings

Extramammary findings are not rare but are infrequently actionable; judicious evaluation prevents unnecessary workups.

Key Points

  • Prevalence ~17–23%; commonly liver, lung/pleura, mediastinum, and bone.
  • Actionable rate is low (~4.5% recommended, ~2.5% performed; malignancy ~0.2%, mostly in patients with prior/current cancer).
  • Prior imaging review and EMR search are critical; many lesions are stable/incidental (e.g., cysts, hemangiomas).
  • On T2: hyperintense bone lesions with enhancement merit attention; unilateral large effusions and pleural enhancement/nodules suggest metastasis.
  • Extra-axillary/sternal and mediastinal findings can alter staging; escalate appropriately.

Background Parenchymal Enhancement (BPE) and Inflammatory Breast Cancer

Recognizing pathological diffuse enhancement requires comparison to contralateral breast and attention to skin involvement.

Key Points

  • BPE categories: minimal, mild, moderate, marked; can be asymmetric. Influenced by hormones, endocrine therapy (tamoxifen reduces), and radiation (early increase, late decrease).
  • BPE is an independent predictor of breast cancer risk and may be more predictive than density in some cohorts.
  • Inflammatory cancer hallmarks: Diffuse NME with skin thickening/enhancement, breast enlargement, and clinical signs (erythema, pruritus, nipple inversion).
  • Use contralateral BPE as a critical comparator; extensive unilateral NME with skin enhancement is pathologic.

MRI-Guided Biopsy Pathology Correlation: Apocrine Metaplasia and Papillary Spectrum

Understanding common benign outcomes on MR biopsy improves concordance assessment and reduces unnecessary surgery.

Key Points

  • Apocrine metaplasia: Often T2 hyperintense with possible washout; histology may mimic papillary fronds; microvascular proliferation explains enhancement.
  • Expect over-representation of papillary lesions and apocrine metaplasia in MR-biopsied targets.
  • Early in practice, adopt a low threshold for discordance; refine with experience and pathologist collaboration.
  • Concordance: Apocrine metaplasia can be benign-concordant for enhancing masses when sampling is complete and imaging–pathology features align.

BI-RADS Assessment Pearls Across Cases

Consistent application of BI-RADS underpins accurate recommendations and reduces unnecessary follow-up or intervention.

Key Points

  • Foci: BI-RADS 2/3 if T2 bright/persistent/stable; upgrade to BI-RADS 4 with T2 hypointensity, washout, or change from prior.
  • NME: Linear/segmental and clustered ring are suspicious; avoid BI-RADS 3. Pursue mammographic correlation for calcifications/biopsy planning.
  • Preoperative imaging: Avoid BI-RADS 3 ipsilaterally; use final categories (not 0) after completing appropriate additional imaging; biopsy lesions that change management.
  • Technical inadequacy: Use BI-RADS 0 and repeat promptly when enhancement/fat sat/positioning are inadequate.

Conclusion

This syllabus distills practical, evidence-informed strategies for interpreting breast MRI and translating findings into precise, patient-centered management. Key tenets include discriminating benign-leaning foci from suspicious ones using T2 signal, kinetics, and interval change; rigorously characterizing NME by distribution and internal pattern (particularly clustered ring for DCIS); mandating mammographic correlation to prevent overcalling and to optimize biopsy guidance; enforcing no BI-RADS 3 in preoperative ipsilateral breasts while biopsying lesions that alter management; ensuring technical adequacy; and remaining vigilant for extramammary disease. Multidisciplinary coordination—with surgeons, technologists, and pathologists—is essential to convert high-quality imaging into optimal clinical outcomes.

Ready to earn credit? Sign up for the Course.